Evidence map›Paper›PMID 39398138›Full record

ArticleACS omega2024

Inhibition of the SARS-CoV-2 Non-structural Protein 5 (NSP5) Protease by Nitrosocarbonyl-Bases Small Molecules.

Marco Leusciatti, Beatrice Macchi, Francesca Marino-Merlo, Valeria Stefanizzi, Antonio Mastino, Giulia Morra, Paolo Quadrelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The strategies and advances of mRNA translation booster.Asian journal of pharmaceutical sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marco LeusciattiDepartment of Chemistry, INSTM Research Unit of Pavia; University of Pavia, Viale Taramelli 10-12, Pavia 27100, Italy.
Beatrice MacchiDepartment of Chemical Science and Technology, University of Rome Tor Vergata, Via della ricerca scientifica 1, Roma 00133, Italy.
Francesca Marino-MerloDepartment of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, 31, Messina 98166, Italy.
Valeria StefanizziDepartment of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, 31, Messina 98166, Italy.
Antonio MastinoDepartment of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, 31, Messina 98166, Italy.
Giulia MorraBiocomputing Lab, SCITEC-Istituto di Scienze e Tecnologie Chimiche CNR, Via Mario Bianco 9, Milano 20131, Italy.ORCID https://orcid.org/0000-0002-9681-7845
Paolo QuadrelliDepartment of Chemistry, INSTM Research Unit of Pavia; University of Pavia, Viale Taramelli 10-12, Pavia 27100, Italy.ORCID https://orcid.org/0000-0001-5369-9140

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present work, we have designed and synthesized potential NSP5 protease allosteric inhibitors exploiting both docking and molecular dynamic data on SARS-CoV-2. The chemical protocols were developed on the basis of 1,3-dipolar cycloaddition reactions as well as the chemistry of nitrosocarbonyl intermediates. Computational studies were first conducted for determining the best candidate for SARS-CoV-2 NSP5 protease inhibition. Selected compounds were submitted to biological tests, showing low cytotoxicity and moderate activity.

Identifiers

PMID39398138
PMCPMC11465462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.